Table 1.
Demographics and clinical features of the study population divided into fracture and non-fracture groups
| Parameter | Variable | Study population N = 447 | Non-fracture group n = 395 (88.4%) | Fracture group n = 52 (11.6%) | p value |
|---|---|---|---|---|---|
| Patients demographics | Median age at diagnosis, years (range) | 27.4 (2–84) | – | – | |
| Mean age at diagnosis, years (SD) | 33.4 (±19.8) | 32.8 (±19.1) | 37.7 (±24.2) | ||
| Male | 260 (58.2%) | 265 (67.1%) | 30 (57.7%) | 0.528 | |
| Female | 187 (41.8%) | 130 (32.9%) | 22 (42.3%) | ||
| Tumour type | Osteosarcoma | 190 (42.5%) | 168 (42.5%) | 22 (42.3%) | 0.524 |
| Chondrosarcoma | 130 (29.2%) | 117 (29.6%) | 13 (25.0%) | ||
| Ewing sarcoma/PNET | 79 (17.7%) | 70 (17.7%) | 9 (17.3%) | ||
| MFH | 41 (9.2%) | 33 (8.4%) | 8 (8.4%) | ||
| Fibrosarcoma | 7 (1.6%) | 7 (1.8%) | 0 | ||
| Tumour location | Upper extremity | 76 (17%) | 67 (17%) | 9 (17%) | 0.297 |
| Lower extremity | 266 (59.5%) | 231 (58.5%) | 35 (67.3%) | ||
| Pelvis/hip | 74 (16.6%) | 70 (17.7%) | 4 (7.7%) | ||
| Others | 31 (6.9%) | 27 (6.8%) | 4 (7.7%) | ||
| Tumour stage | Ia/b | 146 (32.7%) | 139 (35.9%) | 7 (13.5%) | 0.001 |
| IIa/b | 253 (56.6%) | 217 (56.1%) | 36 (69.2%) | ||
| III | 40 (8.9%) | 31 (8.0%) | 9 (17.3%) | ||
| Not available | 8 (1.8%) | – | – | ||
| Response to neoadjuvant chemotherapy | Good response | 127 (28.4%) | 112 (28.4%) | 15 (28.8%) | 0.336 |
| Poor response | 83 (18.6%) | 72 (18.3%) | 11 (21.2%) | ||
| No data available | 62 (13.9%) | 59 (14.8%) | 3 (5.8%) | ||
| Local recurrence | Local recurrence (total study population) | 39 (8.7%) | 33 (8.4%) | 6 (11.5%) | 0.35 |
| Limb salvage | 31 (9.0%) | 26 (8.6%) | 5 (11.9%) | 0.54 | |
| Ablative surgery | 8 (7.8%) | 7 (7.5%) | 1 (10%) | ||
| Distant metastasis | No distant metastasis (tumour stage I + II) | 320 (80.2%) | 286 (80.3%) | 34 (79.1%) | 0.489 |
| Distant metastasis (tumour stage I + II) | 79 (19.8%) | 70 (19.7%) | 9 (20.9%) | ||
| Type of surgery | Limb salvage | 344 (77.0%) | 302 (76.5%) | 42 (80.8%) | 0.496 |
| Ablative surgery | 103 (23.0%) | 93 (23.5%) | 10 (19.2%) | ||
| Resection margins | Wide | 355 (79.4%) | 317 (80.3%) | 38 (73.1%) | 0.360 |
| Marginal | 45 (10.1%) | 39 (9.9%) | 6 (11.5%) | ||
| Intralesional | 47 (10.5%) | 39 (9.9%) | 8 (15.4%) |
SD standard deviation, PNET primitive neuroectodermal tumour, MFH malignant fibrous histiocytoma
Values given as n (%) unless otherwise noted